In patients with progressive idiopathic interstitial pneumonia, a double-blind controlled trial evaluated the safety and tolerability of PC-SOD when administered at doses of 40 mg and 80 mg [36]. The gene discussed is SOD1; the disease is idiopathic interstitial pneumonia.